Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M293,846Revenue $M71,312Net Margin (%)19.4Z-Score5.3
Enterprise Value $M279,344EPS $4.8Operating Margin %25.8F-Score7
P/E(ttm))18.8Cash Flow Per Share $6.2Pre-tax Margin (%)21.7Higher ROA y-yY
Price/Book3.710-y EBITDA Growth Rate %3.1Quick Ratio2.1Cash flow > EarningsY
Price/Sales4.15-y EBITDA Growth Rate %-0.9Current Ratio2.5Lower Leverage y-yN
Price/Cash Flow11.3y-y EBITDA Growth Rate %7.6ROA % (ttm)10.4Higher Current Ratio y-yY
Dividend Yield %2.6Insider Buy (3m)0ROE % (ttm)18.7Less Shares Outstanding y-yY
Payout Ratio %50.0Shares Outstanding M2,829ROI % (ttm)15.4Gross Margin Increase y-yY

Gurus Latest Trades with JNJ

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
JNJYacktman Focused Fund 2014-06-30 Reduce-0.51%$96.54 - $105.76
($101.02)
$ 103.212%Reduce -13.16%3,300,000
JNJDonald Yacktman 2014-06-30 Reduce-0.21%$96.54 - $105.76
($101.02)
$ 103.212%Reduce -5.5%9,045,902
JNJTweedy Browne 2014-06-30 Reduce-0.17%$96.54 - $105.76
($101.02)
$ 103.212%Reduce -1.71%4,196,224
JNJRay Dalio 2014-06-30 Reduce-0.16%$96.54 - $105.76
($101.02)
$ 103.212%Reduce -74.94%65,893
JNJGeorge Soros 2014-06-30 Reduce-0.05%$96.54 - $105.76
($101.02)
$ 103.212%Reduce -51.22%50,000
JNJJoel Greenblatt 2014-06-30 Sold Out -0.01%$96.54 - $105.76
($101.02)
$ 103.212%Sold Out0
JNJJohn Hussman 2014-06-30 Reduce-0.01%$96.54 - $105.76
($101.02)
$ 103.212%Reduce -50%1,325
JNJRay Dalio 2014-03-31 Add0.12%$86.62 - $97.44
($92.6)
$ 103.2112%Add 132.34%262,993
JNJGeorge Soros 2014-03-31 Buy 0.1%$86.62 - $97.44
($92.6)
$ 103.2112%New holding, 102500 sh.102,500
JNJJoel Greenblatt 2014-03-31 Buy 0.01%$86.62 - $97.44
($92.6)
$ 103.2112%New holding, 7496 sh.7,496
JNJJohn Hussman 2014-03-31 Reduce-0.65%$86.62 - $97.44
($92.63)
$ 103.2111%Reduce -97.42%2,650
JNJPRIMECAP Management 2014-03-31 Reduce-0.15%$86.62 - $97.44
($92.6)
$ 103.2112%Reduce -10.14%12,300,986
JNJRay Dalio 2013-12-31 Add0.06%$85.61 - $95.63
($92.24)
$ 103.2112%Add 314.73%113,193
JNJPrem Watsa 2013-12-31 Reduce-15.54%$85.61 - $95.63
($92.24)
$ 103.2112%Reduce -97.12%84,700
JNJGeorge Soros 2013-12-31 Sold Out -1.2%$85.61 - $95.63
($92.24)
$ 103.2112%Sold Out0
JNJVanguard Health Care Fund 2013-12-31 Sold Out -0.85%$85.61 - $95.63
($92.24)
$ 103.2112%Sold Out0
JNJJohn Hussman 2013-12-31 Reduce-0.48%$85.61 - $95.63
($92.24)
$ 103.2112%Reduce -49.35%102,650
JNJJoel Greenblatt 2013-12-31 Sold Out -0.09%$85.61 - $95.63
($92.24)
$ 103.2112%Sold Out0
JNJJoel Greenblatt 2013-09-30 Buy 0.09%$86.17 - $94.39
($89.81)
$ 103.2115%New holding, 32599 sh.32,599
JNJRuane Cunniff 2013-09-30 Add0.03%$86.17 - $94.39
($89.81)
$ 103.2115%Add 420.69%74,495
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

JNJ is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
JNJ James Barrow 2014-06-3017,065,2300.62.4+0.66%
JNJ Jean-Marie Eveillard 2014-06-301,623,4820.060.41+0.37%
JNJ Ruane Cunniff 2014-06-3076,01200.04+0.29%
JNJ Yacktman Fund 2014-06-304,050,0000.143.6
JNJ Tom Gayner 2014-06-30574,2000.021.7
JNJ Richard Perry 2014-06-30342,2770.010.99
JNJ Warren Buffett 2014-06-30327,1000.010.03
JNJ Prem Watsa 2014-06-3084,70000.61
JNJ Dodge & Cox 2014-06-3038,62500
JNJ Michael Price 2014-06-3035,00000.45
JNJ PRIMECAP Management 2014-06-3012,242,4200.431.4-0.48%
JNJ Tweedy Browne 2014-06-304,196,2240.159.4-1.71%
JNJ Donald Yacktman 2014-06-309,045,9020.323.8-5.5%
JNJ Mario Gabelli 2014-06-30373,1860.010.2-5.54%
JNJ Yacktman Focused Fund 2014-06-303,300,0000.123.5-13.16%
JNJ John Hussman 2014-06-301,32500.01-50%
JNJ George Soros 2014-06-3050,00000.04-51.22%
JNJ Ray Dalio 2014-06-3065,89300.05-74.94%
JNJ Joel Greenblatt 2014-06-30000Sold Out
JNJ Meridian Funds 2013-06-307,88500.03
Premium Most recent portfolio changes are included for Premium Members only!


JNJ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
COSGROVE STEPHEN JCorporate Controller 2014-05-05Sell22,000$100.052.91view
Fasolo PeterVP, Global Human Resources 2014-03-14Sell6,824$93.1510.53view
COSGROVE STEPHEN JCorporate Controller 2013-08-14Sell17,200$91.3912.66view
Ullmann Michael HVP, General Counsel 2013-08-05Sell16,140$93.689.91view
Stoffels PaulusChief Scientific Officer 2013-07-25Sell45,440$92.411.43view
Caruso Dominic JVP, Finance; CFO 2013-07-18Sell30,000$90.3114.01view
CULLEN JAMESDirector 2013-05-07Sell4,929$85.420.56view
LINDQUIST SUSAN LDirector 2012-12-07Sell7,600$70.0247.04view
CULLEN JAMESDirector 2012-11-12Sell13,900$69.747.72view
Caruso Dominic JCFO 2012-10-19Sell20,400$71.9543.1view

Press Releases about JNJ :

    Quarterly/Annual Reports about JNJ:

    News about JNJ:

    Articles On GuruFocus.com
    A Few Reasons Why Investors Should Consider Dendreon for Their Portfolio Aug 15 2014 
    A Strong Candidate for Investor´s Portfolios Aug 12 2014 
    5 Dividend Stocks Delivering The Secret To Successful Investing Aug 06 2014 
    5 Dividend Stocks Delivering The Secret To Successful Investing Aug 05 2014 
    Why Procter & Gamble Surged Higher On Friday? Aug 03 2014 
    Outlook for August 2014 Aug 01 2014 
    Limiting Risk: A Little Exposure To High Yield Goes A Long Way Jul 29 2014 
    What’s the Right PE Ratio? Jul 29 2014 
    Is Ken Fisher a Dividend Growth Investor? Jul 27 2014 
    Just Post-It: 3M Is a Good Bet for Your Portfolio Today Jul 24 2014 

    More From Our Partners
    Earnings Season Is The Right Prescription For Health Care ETFs Aug 12 2014 - BENZINGA

    More From Other Websites
    This stock may be hazardous to your financial health Aug 19 2014
    Allergan approaches Salix to fight Valeant bid Aug 19 2014
    Scientists racing to test Ebola vaccines in humans Aug 14 2014
    Robert Wood Johnson's New Industry Made Surgery Safer Aug 14 2014
    [video] Global risk playbook Aug 12 2014
    Intercept Pharma Soars On Liver-Disease Drug Data Aug 12 2014
    Entia Biosciences' Supplements Could Prevent Dementia Aug 12 2014
    JOHNSON & JOHNSON Financials Aug 08 2014
    Medivation Cancer Drug Fuels Beat, Swings To Profit Aug 08 2014
    [video] Inside Johnson & Johnson (08/05) Aug 08 2014
    3 Companies That Should Benefit From The New Initiative In Africa Aug 07 2014
    Ebola Has Landed Aug 05 2014
    Johnson & Johnson Can Only Get Better When It Gets Cheaper Aug 05 2014
    Amgen Cancer Drug Kyprolis Succeeds In Trial Aug 04 2014
    Richard K. Matros, the President, CEO and Chairman of Sabra Health Care REIT, Inc. (SBRA),... Aug 04 2014
    JOHNSON & JOHNSON Files SEC form 10-Q, Quarterly Report Aug 01 2014
    Medical-Device Excise Tax: The Case For Repeal Needs New Arguments Aug 01 2014
    Pharmacyclics Q2 Earnings Get Mixed Reception Aug 01 2014
    What Does a Multibillion-Dollar Corporation Want With Crowdfunding? Aug 01 2014
    [video] Johnson & Johnson Device Recall Unlikely to Affect Company Financials Jul 31 2014

    Add Notes, Comments or Ask Questions

    User Comments

    Gurufocus
    ReplyGurufocus - 10 months ago
    test
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide